drugset / Trial / NCT00006098
PS-341 in Treating Patients With Hematologic Cancer
Treatment
Summary
RATIONALE: PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have hematologic cancer.
Timeline
- Start
- 2000-04
- Primary completion
- 2001-10
- Completion
- 2001-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Intravenous |